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abstract | systemic lupus erythematosus (sLe) is a chronic, relapsing–remitting, multisystemic autoimmune 
inflammatory disorder that predominantly affects women of childbearing age. Much has been written about the 
clinical course and long-term damage associated with sLe, as well as the reduced life expectancy of patients 
with this condition. in addition, studies have emphasized the socioeconomic and psychosocial impact of sLe, 
although the monetary cost of caring for patients with the disorder has only been evaluated in a modest number 
of studies and a restricted number of countries. sLe has a negative impact on quality of life and is associated 
with high health-care costs and significant productivity loss. Factors associated with increased cost of sLe 
include long disease duration, high disease activity and damage, poor physical and mental health, and high 
education and employment levels. similarly, high disease activity and damage, poor physical health, certain 
disease manifestations, as well as poor family and social support are associated with poor health-related 
quality of life outcomes. sLe incurs a great burden on both the patient and society. Long-term prospective 
studies should be encouraged to monitor the costs and psychosocial impact of this condition, and to better 
understand the factors that are associated with poor outcomes.
Lau, C. s. & Mak, A. Nat. Rev. Rheumatol. advance online publication XX June 2009; doi:10.1038/nrrheum.2009.106
The scope of the problem
Few conditions inflict as much physical and functional 
disability as systemic lupus erythematosus (sle). there 
is currently no cure for sle, and the disease can result in 
multisystem failure and even death. sle incurs a signifi­
cant burden both to patients and to society as a whole. 
evidence from the last few decades has shown that uncon­
trolled disease and infectious complications are respon­
sible for the majority of adverse outcomes in patients with 
sle.1,2 However, tremendous improvements have been 
seen in the short­term and medium­term survival of these 
patients owing to earlier diagnosis, judicious use of potent 
immunosuppressive agents, meticulous monitoring of 
disease activity and the availability of powerful antibiotics 
for the treatment of infective complications.3 nonetheless, 
the long­term prognosis of sle remains poor because of 
chronic tissue and organ damage pertaining either to the 
disease itself or its treatment. unlike infections and disease 
flares, which are episodic and largely amenable to therapy, 
sle damage is mostly irreversible, cumulative and poten­
tially life­threatening.
early disease damage has been shown to have a signifi­
cant impact on the long­term survival of patients with 
sle. a report from rahman et al.4 in toronto, Canada, has 
shown that a significantly greater number of patients with 
early disease damage, defined as the presence of damage 
at initial assessment, died within 10 years compared with 
patients who had no early damage. a later prospective 
study revealed that overall damage accrued as early as 
1 year after the diagnosis of sle could predict mortality.5 
of the various organs and tissues that are susceptible to 
sle­related damage, the cardiovascular system is associ­
ated with the most substantial long­term morbidity and 
premature mortality.6–8 notably, among premenopausal 
women, a group that is usually protected from coronary 
events, the incidence of myocardial infarction has been 
shown to be more than 50 times higher in those with sle 
compared with healthy individuals.6 Based on a 36­year 
observational study of the university of toronto lupus 
Clinic cohort, urowitz et al.9 reported that cardiovascular 
disease and overall sle­related damage are strong predic­
tors of all­cause mortality. Despite improvements in disease 
activity control and overall disease survival over the dura­
tion of the study, the authors observed increases both in 
cumulative organ damage and in the incidence of coronary 
artery disease, both of which had significant detrimental 
effects on disease prognosis. although not as prevalent 
as cardiovascular disease, other life­ threatening damage, 
such as renal and pulmonary disease, has also been shown 
to predict mortality.4,10 in a recent study reported by 
Danila et al.,11 of all the domains of the systemic lupus 
international Collaborating Clinics/american College of 
rheumatology Damage index (sDi), renal damage was 
found to be the most important predictor of mortality.
interestingly, although neuropsychiatric disease and 
osteoporotic fracture have been shown to be highly 
prevalent in several sle cohorts, studies of their effects 
on the mortality of patients with sle are surprisingly 
scarce. in a cohort study of 282 Chinese patients with a 
mean follow­up period of 6.7 years, neuropsychiatric 
damage was not predictive of mortality.12 similarly, fra­
gility fractures, which are reported in 6–20% of patients 
with sle in the us, europe and China,13–16 have not been 
shown to predict mortality, in contrast to observations of 
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postmenopausal women with osteoporotic fractures in the 
general population.
a wealth of evidence exists to describe the effects of sle 
on the life expectancy of a patient. However, unlike other 
chronic rheumatic conditions, such as rheumatoid arthri­
tis and osteoarthritis, there is a comparative lack of data 
on the socioeconomic burden of sle. evidence suggests 
that socioeconomic status is a crucial component of long­
term survival in patients with sle.17 thus, it is important 
to address the magnitude of the problem and understand 
the factors that might affect the socioeconomic burden 
of the disease, including the health service costs of caring 
for a patient with sle. the relevance of health­care costs 
is brought to the fore by the recent global economic down­
turn and the advent of new treatments for sle. improved 
knowledge in this area will allow health­care policy makers 
to explore specific cost drivers and decide how best to allo­
cate health­care and research resources.
The socioeconomic cost of SLE
owing to the nature of the condition, estimating the 
socioeconomic cost of sle poses a challenge to research­
ers. sle is characterized by a chronic remitting–relapsing 
course and a wide range of disease­associated and unre­
lated factors that not only entail health­care expenditure, 
such as physician consultation and diagnostic and thera­
peutic procedures, but also impose a significant burden 
on patients’ health­related quality of life (HrQol), 
work­related disability and other expenditures that are 
more difficult to measure. Crucially, sle predominantly 
affects young women, who constitute the majority of the 
Key points
systemic lupus erythematosus (sLe) has a significant negative impact on a  ■
patient’s quality of life, and is associated with high health-care costs and loss 
of productivity
increased disease activity and damage, poor physical health, and poor family and  ■
social support are associated with a reduced quality of life in patients with sLe
Patients with certain manifestations sLe, such as disfiguring cutaneous  ■
disease, have a worse quality of life than patients without these manifestations
Health-care costs are higher in patients with a long disease duration, high   ■
sLe disease activity and damage, poor physical and mental health, and  
high education and employment level
Long-term prospective studies are needed to evaluate the costs of sLe and to  ■
assist policymakers in the future elaboration of health-care resource planning 
and allocation
non­labor, domestic workforce; such difficult­to­measure 
yet essential burdens, therefore, need to be addressed 
properly and factored into the overall cost estimation.18 
a number of cohort studies have shown that overall sle­
related damage is associated with work disability and loss 
of produc tivity,19–21 and is detrimental to both the physi­
cal and mental functioning of a patient.22 the various 
terms used in evaluating the socioeconomic costs of sle 
are defined in Box 1, and are further discussed in the 
supplementary information online.
Direct and indirect monetary costs
the main findings of the available studies that have 
investi gated the monetary costs of sle are summarized 
in table 1. the tri­nation study involved over 700 patients 
from Canada, uK and the u , and was the first prospec­
tive study to estimate and compare the cost of caring for 
patients with sle, and assess the relationship of this cost to 
disease characteristics and outcome.18,23,24 as well as studies 
from Canada25 and the uK,26 data from two large­scale 
studies from Germany27 and the us28 are now available.
Despite the relative paucity of studies, all have shown 
that substantial costs are incurred in the care of patients 
with sle. in the tri­nation study, the annual total direct 
health­care costs (based on the value of CaD$ in 2002) 
were CaD$4,968, CaD$4,763 and CaD$5,055 in Canada, 
the uK and the us, respectively.24 notably, although 
patients with sle in Canada and the uK spent 20% and 
13% less on direct resources, respectively, than their us 
counterparts, they did not experience inferior outcomes 
in terms of disease damage and physical and mental well­
being.24 During a similar period, a study comprising 844 
German patients with sle revealed that the annual direct 
health­care cost for one patient was €3,191,27 which is rela­
tively similar to that of Canada in the tri­nation study.29 
in a study from 2008, which included 815 patients with 
sle in the us, the annual direct health­care cost for a 
single patient with sle was estimated to be approximately 
us$13,000, with the indirect cost exceeding us$8,600.28
almost all of the related studies have demonstrated that 
indirect costs constitute the majority of the total cost.24–27,30 
sutcliffe and colleagues26 demonstrated that the indirect 
cost constituted approximately two­thirds of the total cost. 
in the tri­nation study, indirect costs were shown to be 
between 2.4 and 2.8 times higher than the corresponding 
direct costs;30 and in Germany, the indirect costs were two 
times higher than the direct costs of caring for a patient 
with sle.27
Factors associated with higher cost
multiple regression analyses have demonstrated that 
long disease duration, more­active disease,27 high 
 disease­related damage24,26,29 and poor physical and 
mental health28 were associated with higher direct costs, 
whereas older age,26 more­active disease,24,28 longer 
disease duration,27 disease­related damage29 and poorer 
HrQol26 were associated with higher indirect costs. 
interestingly, in one study, higher educational level 
Box 1 | Definitions of terms used to estimate the socioeconomic costs of sLe 
[eD: changed to sLe to fit onto 1 line, ok?]
Direct cost: expenditures for diagnosis, treatment, continuing care and 
rehabilitation.
indirect cost: loss of productivity due to illness, including both diminished labor 
market and non-labor or household activity (for example, housekeeping and 
childcare).
intangible costs: expenditures that are more difficult to measure, mainly the 
assessment of health-related quality of life.
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Table 1 | Major findings of sLe cost-of-illness studies
Study Clarke et al. 
(1993)25
Sutcliffe et al. 
(2001)26
Clarke et al. 
(1999)23
Clarke et al. 
(2004)24
Panopalis et al. 
(2007)30
huscher et al. 
(2006)27
Panopalis et al. 
(2008)28
recruitment 
period
Jan 1990 
to Jan 1991
Jul 1995 
to Jul 1997
Jun 1995  
to Feb 1998
Jul 1995  
to Feb 1998
Jul 1995  
to Feb 1998
2002 2002–2005
study type Cross-sectional 
analysis 
(preceding 
6 months)
Prospective 
analysis 
(6 months)
Cross-sectional 
analysis (preceding 
6 months)
Prospective 
analysis  
(4 years)
Prospective 
analysis  
(4 years)
Prospective 
analysis 
(12 months)
Prospective 
analysis 
(12 months)
Country, 
number of 
patients
Canada: 164 UK: 105 Tri-Nation study
Canada: 229 
UsA: 268 
UK: 211 
Total: 778
Tri-Nation study 
Canada:162 
UsA: 157 
UK:166 
Total: 485
Tri-Nation study 
Canada: 162 
UsA: 157 
UK: 166 
Total: 485
Germany: 844 UsA: 812
Mean age, 
years
45.0 (range 
16.3–85.6)
39.9 (range 
18.8–75.3)
Canada: 
43.3 ± 13.8 
UsA: 39 ± 11.9 
UK: 40.7 ± 12.1
Canada: 42.4 
(95% Ci 
40.3–44.4) 
UsA: 39.1 (95% 
Ci 37.4–40.8) 
UK: 40.0 (95% Ci 
38.2–41.7)
Canada: 42.4 (95% 
Ci 40.3–44.4) 
UsA: 39.1 (95% Ci 
37.4–40.8) 
UK: 40.0 (95% Ci 
38.2–41.7)
42f 48.2 ± 12.8h
Mean 
duration of 
sLe, years
13.5 (range 
0.1–40.6)
10.5 (range 
1–33.5)
Canada: 10.2 ± 7.4 
UsA: 8.6 ± 6.2 
UK: 10.0 ± 7.1
Canada: 9.9 (95% 
Ci 8.7–11.1) 
UsA: 8.6 (95% Ci 
7.6–9.6) 
UK: 10.0 (95% Ci 
9.0–11.1)
Canada: 9.9 (95% 
Ci 8.7–11.1) 
UsA: 8.6(95% Ci 
7.6–9.6) 
UK: 10.0 (95% Ci 
9.0–11.1)
NA 13.7 ± 8.5
Patients in 
employment 
%
44 54.3 NA NA Canada: 48.7 
UsA: 45.3 
UK: 52.6
55 48.7
Mean 
annual 
direct cost
CAD$6,023a 
(2009 
Us$7,102)
£2,613b 
(2009 
Us$4,784)
Canada: 
CAD$4,853c  
(2009 Us$4,953) 
UsA: CAD$5,285c 
(2009 Us$4,949) 
UK: CAD$4,760c 
(2009 Us$4,457)
Canada: 
CAD$3,961d 
(2009 Us$3,709) 
UsA: CAD$5,061d 
(2009 Us$4,739) 
UK: CAD$4,412d 
(2009 Us$4,131)
NA €3,191g 
(2009 
Us$3,369)
Us$12,643i 
(2009 
Us$14,202)
Mean 
annual 
indirect cost
CAD$7,071a 
(2009 
Us$8,422)
£5,299b 
(2009 
Us$10,241)
NA NA eCanada: 
CAD$11,024d 
(2009 Us$10,323) 
eUsA: 
CAD$15,499d 
(2009 Us$14,513) 
eUK:  
CAD$12,696d 
(2009 Us$11,889)
€11,220g 
(2009 
Us$11,845)
Us$8,659i  
(2009  
Us$9,727)
Mean 
annual total 
cost
CAD$13,094a 
(2009 
Us$15,524)
£7,913b 
(2009 
Us$11,652)
NA NA NA €14,411g 
(2009 
Us$15,213)
Us$20,924i 
(2009 
Us$23,504)
indicators 
for high 
direct cost
High creatinine; 
poor physical 
function
High disease 
activity;  
high disease 
damage;  
poor physical 
function; high 
education 
level
NA NA NA High disease 
activity; short 
duration of 
disease; 
low functional 
status
High disease 
activity;  
long disease 
duration;  
poor physical 
health;  
poor mental 
health
indicators 
for high 
indirect cost
Low sLe 
well-being; weak 
social support; 
high education 
level and 
employment
High disease 
activity;  
poor physical 
function; high 
education 
level
NA NA NA Advanced age; 
long duration 
of disease; 
low functional 
status
Advanced age; 
high disease 
activity;  
poor physical 
health; poor 
mental health
For ease of reference, the monetary cost of sLe reported in these studies is also expressed in UsD; exchange rates are correct as of April 2009. a1990 Canadian Dollars. b1996 sterling 
Pounds. c1997 Canadian Dollars. d2002 Canadian Dollars. esum of the cumulative indirect cost as a result of diminished labor market activity and cumulative indirect cost owing to non-labor 
market activity (replacement cost, 50%). fPatients of working age (<65 years) were studied. g2002 euros. hPatients of working age (≥18 and <65 years) were studied. i2004 Us Dollars. 
Abbreviations: NA, not available; sLe, systemic lupus erythematosus.
[eD: country row removed and added to number of patients to fit table onto 1 page. ok?]
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was found to incur increased direct health­care costs 
compared with a lower level of education.26 this phe­
nomenon is probably related to better follow­up and 
medication compliance amongst patients who are well 
educated. Because of their higher earning power, the loss 
of productivity and subsequent indirect cost to the labor 
market would also be proportionally higher in better­
educated patients with sle.26
Impact of Sle on hrQol
most chronic illnesses affect patients’ HrQol, self­
esteem, family and marital relationships and psycho social 
health. these intangible costs are difficult to evaluate, 
and most studies have focused mainly on the dis crepancy 
of HrQol. a number of early studies confirmed that 
patients with sle have a poorer HrQol compared with 
healthy individuals.31–38 the medical outcomes study 
(mos) short form (sF)­36 questionnaire is the most 
commonly used tool to evaluate the HrQol of patients 
with sle.39 the questionnaire consists of eight domains 
that measure important physical and mental compo­
nents of health: physical function, role physical, bodily 
pain, general health, mental health, role emotional, social 
function and vitality. significant decrements have been 
observed in all eight domains of the sF­36 across groups 
of sle patients of different ethnicities.33–35 in addition, 
studies have shown that the effects of sle on HrQol are 
comparable to those in other chronic diseases, some of 
which might be perceived as being more severe than sle, 
including aiDs, rheumatoid arthritis, psoriatic arthritis, 
hypertension, diabetes, post­myocardial infarction and 
congestive heart failure.40–42
in addition, factors related to patient demo graphics, 
disease and therapy have been shown to influence the 
HrQol of patients with sle. For example, a study from 
the netherlands showed that patients with sle who 
were unemployed had lower HrQol than those who 
were employed.43 similarly, young age at diag nosis, a 
short disease duration, poor physical health, low family 
support, a sense of helplessness and use of cytotoxic drugs 
have been shown to be associated with worse HrQol in 
patients with sle.35
Furthermore, cross­sectional studies have shown that 
certain manifestations of sle, such as end­stage renal 
disease40 and cutaneous disease (particularly alopecia and 
discoid lupus lesions45) are associated with poorer HrQol 
irrespective of overall disease activity. However, prospec­
tive clinical trials, which allow examination of a cause­
and­effect relationship, have shown that improvements 
in overall disease activity are associated with improved 
HrQol.37,46 interestingly, although some therapeutic 
interventions can be equally effective in controlling certain 
disease complications, their effects on HrQol can differ. 
For example, a recent study from Hong Kong showed that 
induction of immunosuppression using mycophenolate 
mofetil for the treatment of severe sle­related nephritis 
was associated with better HrQol than oral cyclophos­
phamide therapy, despite the two interventions having 
a similar therapeutic effect.47 Disease damage has been 
shown to be associated with decreased physical, social 
and mental functioning.35,36,48 Furthermore, any new organ 
damage might predict a further decline in HrQol.48
these observations highlight the importance of measur­
ing HrQol when evaluating the burden of sle. although 
the sF­36 has several features that make it a suitable instru­
ment for measuring HrQol in patients with sle, it is not 
disease specific. sle­specific measures are, however, being 
developed.41,49–51 For example, the sle­specific quality­of­
life instrument (sleQol) is a 40­item questionnaire in 
the english language that has been validated for use in 
patients with sle in singapore.51 similarly, the lupusQol, 
a 34­item questionnaire that covers eight disease­related 
domains defined by patients as being important,50 and the 
55­item l­Qol questionnaire51 have been developed and 
validated for use in the uK. using the rasch model for 
analysis, the l­Qol was shown to be a valuable instrument 
for assessing patient­based outcomes in clinical trials in 
various cohorts of different localities.51 until further cul­
tural adaptation and validation is undertaken, however, the 
use of these instruments remains limited to singaporean 
Chinese49 and British white populations.50,51
Conclusions and future directions
improvements in the diagnosis and management of sle 
mean that patients are living longer, and the burden of 
disease at both personal and societal levels is expected 
to increase. Furthermore, although sle is less common 
than other rheumatologic disorders, its predilection for 
the younger and more productive members of the general 
population makes it essential that we have a better under­
standing of the various costs associated with the disease. 
although cost­of­illness studies have been criticized for 
their limitations as a result of possible measurement errors, 
recall biases and poor comparability across studies, they 
are a valuable tool to assist policymakers in planning and 
allocating health­care resources. early studies have shown 
that sle is associated with significant health­care costs 
and impaired patient quality of life. longer­term prospec­
tive studies are needed to continue to monitor the impact 
of sle, especially considering that patient characteristics, 
disease prognosis, treatment strategies and the finan­
cial climate are ever­changing dynamic processes. more 
importantly, these types of studies are urgently required in 
the asia–Pacific region, which houses the majority of the 
world’s sle patients,52 and where the enormous disparity 
in the needs of patients with sle and resources available 
are a major concern.
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